Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Laura Della Corte is active.

Publication


Featured researches published by Laura Della Corte.


Brain | 2010

SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson’s disease

Pablo Garcia-Reitböck; Oleg Anichtchik; Arianna Bellucci; Mariangela Iovino; Chiara Ballini; Elena Fineberg; Bernardino Ghetti; Laura Della Corte; PierFranco Spano; George K. Tofaris; Michel Goedert; Maria Grazia Spillantini

The pre-synaptic protein alpha-synuclein is the main component of Lewy bodies and Lewy neurites, the defining neuropathological characteristics of Parkinsons disease and dementia with Lewy bodies. Mutations in the alpha-synuclein gene cause familial forms of Parkinsons disease and dementia with Lewy bodies. We previously described a transgenic mouse line expressing truncated human alpha-synuclein(1-120) that develops alpha-synuclein aggregates, striatal dopamine deficiency and reduced locomotion, similar to Parkinsons disease. We now show that in the striatum of these mice, as in Parkinsons disease, synaptic accumulation of alpha-synuclein is accompanied by an age-dependent redistribution of the synaptic SNARE proteins SNAP-25, syntaxin-1 and synaptobrevin-2, as well as by an age-dependent reduction in dopamine release. Furthermore, the release of FM1-43 dye from PC12 cells expressing either human full-length alpha-synuclein(1-140) or truncated alpha-synuclein(1-120) was reduced. These findings reveal a novel gain of toxic function of alpha-synuclein at the synapse, which may be an early event in the pathogenesis of Parkinsons disease.


Journal of Neurochemistry | 2009

Neuro-inflammation induced in the hippocampus of 'binge drinking' rats may be mediated by elevated extracellular glutamate content

Roberta J. Ward; Maria Alessandra Colivicchi; Rachel Allen; François Schol; Frédéric Lallemand; Philippe De Witte; Chiara Ballini; Laura Della Corte; David T. Dexter

The neuropathological and immune changes induced in the brain by ‘binge drinking’ have been investigated in a rat model. Evidence of neuro‐inflammation was identified in the ‘binge drinking’ rat model of alcohol abuse after 3 weeks of administration of 2 or 3 g/kg ethanol (EtOH), three times per day for two consecutive days, followed by 5 days of abstinence: Firstly, alveolar macrophages, isolated from these animals, showed significant increases in inducible nitric oxide synthase, as assayed by nitrite release, both before and after lipopolysaccaharide stimulation. Secondly, significant numbers of activated microglia were present in the dentate gyrus region of the hippocampus of the ‘binge drinking’ model, after major histocompatibility complex class II staining, by comparison with the control. Microdialysis studies in the ventral hippocampus identified a significant increase in the basal extracellular concentration of glutamate, in both the 2 and 3 g/kg administered ‘binge drinking’ rats. In contrast, no changes in the hippocampal extracellular concentrations, of GABA and taurine, or the dopamine and serotonin metabolites were observed under basal conditions. A further dose of EtOH induced a significant decrease in the concentrations of both 3,4‐dihydroxyphenylacetic acid and 5‐hydroxyindoleacetic acid, whereas glutamate, taurine and GABA levels were unaffected. There was no evidence that EtOH preference was initiated by the ‘binge drinking’ regimen. Our results suggest that the possible toxicity associated with ‘binge drinking’ maybe directed by the elevated glutamate levels, which in turn, activate phagocytic cells to release their inflammatory cytokines and chemokines, ultimately leading to neuro‐inflammation.


Cellular and Molecular Life Sciences | 2011

Highly reactive oxygen species: detection, formation, and possible functions

Wolfhardt Freinbichler; Maria Alessandra Colivicchi; Chiara Stefanini; Loria Bianchi; Chiara Ballini; Bashkim Misini; Peter Weinberger; Wolfgang Linert; Damir Varešlija; Keith F. Tipton; Laura Della Corte

The so-called reactive oxygen species (ROS) are defined as oxygen-containing species that are more reactive than O2 itself, which include hydrogen peroxide and superoxide. Although these are quite stable, they may be converted in the presence of transition metal ions, such as Fe(II), to the highly reactive oxygen species (hROS). hROS may exist as free hydroxyl radicals (HO·), as bound (“crypto”) radicals or as Fe(IV)-oxo (ferryl) species and the somewhat less reactive, non-radical species, singlet oxygen. This review outlines the processes by which hROS may be formed, their damaging potential, and the evidence that they might have signaling functions. Since our understanding of the formation and actions of hROS depends on reliable procedures for their detection, particular attention is given to procedures for hROS detection and quantitation and their applicability to in vivo studies.


Journal of Neural Transmission | 2011

Iron and the immune system

Roberta J. Ward; Robert R. Crichton; Deanna L. Taylor; Laura Della Corte; Surjit Kaila Srai; David T. Dexter

Iron and immunity are closely linked: firstly by the fact that many of the genes/proteins involved in iron homoeostasis play a vital role in controlling iron fluxes such that bacteria are prevented from utilising iron for growth; secondly, cells of the innate immune system, monocytes, macrophages, microglia and lymphocytes, are able to combat bacterial insults by carefully controlling their iron fluxes, which are mediated by hepcidin and ferroportin. In addition, lymphocytes play an important role in adaptive immunity. Thirdly, a variety of effector molecules, e.g. toll-like receptors, NF-κB, hypoxia factor-1, haem oxygenase, will orchestrate the inflammatory response by mobilising a variety of cytokines, neurotrophic factors, chemokines, and reactive oxygen and nitrogen species. Pathologies, where iron loading and depletion occur, may adversely affect the ability of the cell to respond to the bacterial insult.


Journal of Pharmacology and Experimental Therapeutics | 2010

Regional Differential Effects of the Novel Histamine H3 Receptor Antagonist 6-[(3-Cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254) on Histamine Release in the Central Nervous System of Freely Moving Rats

Patrizia Giannoni; Andrew D. Medhurst; Maria Beatrice Passani; Maria Grazia Giovannini; Chiara Ballini; Laura Della Corte; Patrizio Blandina

After oral administration, the nonimidazole histamine H3 receptor antagonist, 6-[(3-cyclobutyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl)oxy]-N-methyl-3-pyridinecarboxamide hydrochloride (GSK189254), increased histamine release from the tuberomammillary nucleus, where all histaminergic somata are localized, and from where their axons project to the entire brain. To further understand functional histaminergic circuitry in the brain, dual-probe microdialysis was used to pharmacologically block H3 receptors in the tuberomammillary nucleus, and monitor histamine release in projection areas. Perfusion of the tuberomammillary nucleus with GSK189254 increased histamine release from the tuberomammillary nucleus, nucleus basalis magnocellularis, and cortex, but not from the striatum or nucleus accumbens. Cortical acetylcholine (ACh) release was also increased, but striatal dopamine release was not affected. When administered locally, GSK189254 increased histamine release from the nucleus basalis magnocellularis, but not from the striatum. Thus, defined by their sensitivity to GSK189254, histaminergic neurons establish distinct pathways according to their terminal projections, and can differentially modulate neurotransmitter release in a brain region-specific manner. Consistent with its effects on cortical ACh release, systemic administration of GSK189254 antagonized the amnesic effects of scopolamine in the rat object recognition test, a cognition paradigm with important cortical components.


Journal of Cell Science | 2015

α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons.

Michela Zaltieri; Jessica Grigoletto; Francesca Longhena; Laura Navarria; Gaia Favero; Stefania Castrezzati; Maria Alessandra Colivicchi; Laura Della Corte; Rita Rezzani; Marina Pizzi; Fabio Benfenati; Maria Grazia Spillantini; Cristina Missale; PierFranco Spano; Arianna Bellucci

ABSTRACT The main neuropathological features of Parkinsons disease are dopaminergic nigrostriatal neuron degeneration, and intraneuronal and intraneuritic proteinaceous inclusions named Lewy bodies and Lewy neurites, respectively, which mainly contain α-synuclein (α-syn, also known as SNCA). The neuronal phosphoprotein synapsin III (also known as SYN3), is a pivotal regulator of dopamine neuron synaptic function. Here, we show that α-syn interacts with and modulates synapsin III. The absence of α-syn causes a selective increase and redistribution of synapsin III, and changes the organization of synaptic vesicle pools in dopamine neurons. In α-syn-null mice, the alterations of synapsin III induce an increased locomotor response to the stimulation of synapsin-dependent dopamine overflow, despite this, these mice show decreased basal and depolarization-dependent striatal dopamine release. Of note, synapsin III seems to be involved in α-syn aggregation, which also coaxes its increase and redistribution. Furthermore, synapsin III accumulates in the caudate and putamen of individuals with Parkinsons disease. These findings support a reciprocal modulatory interaction of α-syn and synapsin III in the regulation of dopamine neuron synaptic function. Summary: Absence or aggregation of α-synuclein induces a selective increase and redistribution of synapsin III, reorganizing synaptic vesicle pools, which could have implications for dopamine neuron degeneration in Parkinsons disease.


Biochemical Pharmacology | 1977

Effects of monocyclic compounds on biomembranes.

Giampietro Sgaragli; Laura Della Corte; Margherita Rizzotti-Conti; A. Giotti

Abstract Monocyclic compounds with an aliphatic chain containing at least 2 carbon atoms, interact with biomembranes producing solubilization of proteins. Plasma membrane seems to be more sensitive than mitochondrial-lysosomal membrane to the damaging effects of these compounds. Studies on the structure-activity relationship have shown that benzene derivatives were more active than other compounds having either a etherocyclic or a saturated hexacarbon ring. Among tert.-butylbenzene derivatives, 2,tert.-butyl,4 methoxyphenol (BHA) and 3,5,di-tert.-butyl, 4, hydroxytoluene (BHT) exerted the most remarkable effects. It is suggested that the electronic density on the aromatic nucleus plays an important role on the interaction of monocyclic compounds with membrane constituents.


European Journal of Neuroscience | 2006

Differential effect of cannabinoid agonists and endocannabinoids on histamine release from distinct regions of the rat brain

Gabriele Cenni; Patrizio Blandina; Ken Mackie; Daniele Nosi; Lucia Formigli; Patrizia Giannoni; Chiara Ballini; Laura Della Corte; Pier Francesco Mannaioni; M. Beatrice Passani

Cannabinoids exert complex actions on neurotransmitter systems involved in cognition, locomotion, appetite, but no information was available so far on the interactions between the endocannabinoid system and histaminergic neurons that command several, similar behavioural states and memory. In this study, we investigated the effect of cannabimimetic compounds on histamine release using the microdialysis technique in the brain of freely moving rats. We found that systemic administration of the cannabinoid receptors 1 (CB1‐r) agonist arachidonyl‐2′chloroethylamide/N‐(2chloroethyl)‐5Z,8Z,11Z,14Z‐eicosatetraenamide (ACEA; 3 mg/kg) increased histamine release from the posterior hypothalamus, where the histaminergic tuberomamillary nuclei (TMN) are located. Local infusions of ACEA (150 nm) or R(+)‐methanandamide (mAEA; 1 µm), another CB1‐r agonist, in the TMN augmented histamine release from the TMN, as well as from two histaminergic projection areas, the nucleus basalis magnocellularis and the dorsal striatum. When the endocannabinoid uptake inhibitor AM404 was infused into the TMN, however, increased histamine release was observed only in the TMN. The cannabinoid‐induced effects on histamine release were blocked by co‐administrations with the CB1‐r antagonist AM251. Using double‐immunofluorescence labelling and confocal laser‐scanning microscopy, CB1‐r immunostaining was found in the hypothalamus, but was not localized onto histaminergic cells. The modulatory effect of cannabimimetic compounds on histamine release apparently did not involve inhibition of γ‐aminobutyric acid (GABA)ergic neurotransmission, which provides the main inhibitory input to the histaminergic neurons in the hypothalamus, as local infusions of ACEA did not modify GABA release from the TMN. These profound effects of cannabinoids on histaminergic neurotransmission may partially underlie some of the behavioural changes observed following exposure to cannabinoid‐based drugs.


Journal of Neurochemistry | 2008

Validation of a robust and sensitive method for detecting hydroxyl radical formation together with evoked neurotransmitter release in brain microdialysis

Wolfhardt Freinbichler; Maria Alessandra Colivicchi; Manuela Fattori; Chiara Ballini; Keith F. Tipton; Wolfgang Linert; Laura Della Corte

Sodium terephthalate was shown to be a new robust and sensitive chemical trap for highly reactive oxygen species (hROS), which lacks the drawbacks of the salicylic acid method. Reaction of the almost non‐fluorescent terephthalate (TA2−) with hydroxyl radicals or ferryl‐oxo species resulted in the stoichiometric formation of the brilliant fluorophor, 2‐hydroxyterephthalate (OH‐TA). Neither hydrogen peroxide nor superoxide reacts in this system. This procedure was validated for determining hROS formation during microdialysis under in vivo conditions as well as by in vitro studies. The detection limit of OH‐TA in microdialysis samples was 0.5 fmol/μL. Derivatization of samples with o‐phthalaldehyde, for amino acid detection, had no effect on OH‐TA fluorescence, which could easily be resolved from the amino acid derivatives by HPLC, allowing determination in a single chromatogram. Use of terephthalate in microdialysis experiments showed the neurotoxin kainate to evoke hROS formation in a dose‐dependent manner. The presence of TA2− in the perfusion fluid did not affect basal or evoked release of aspartate, glutamate, taurine and GABA. Assessment of cell death ‘ex vivo’ showed TA2− to be non‐toxic at concentrations up to 1 mM. The in vitro results in the Fenton system (Fe2+ + H2O2) indicate a mechanism whereby TA2− forms a primary complex with Fe2+ followed by an intramolecular hydroxylation accompanied by intramolecular electron transfer.


Brain Research Bulletin | 2008

Neurotensin modulation of acetylcholine, GABA, and aspartate release from rat prefrontal cortex studied in vivo with microdialysis.

Polina Petkova-Kirova; Angelina Rakovska; Laura Della Corte; Galina Zaekova; R. Radomirov; Aliz Mayer

The effects of the peptide transmitter neurotensin (NT) on the release of acetylcholine (ACh), gamma-aminobutyric acid (GABA), glutamate (Glu), aspartate (Asp), and taurine from the prefrontal cortex (PFC) of freely moving rats were studied by transversal microdialysis. Neurotensin (0.2 and 1 microM) administered locally in the PFC produced a concentration-dependent increase in the extracellular levels of ACh, GABA, and Asp, but not of Glu or taurine. The increase produced by 1 microM NT reached a maximum of about 240% for ACh, 370% for GABA, and 380% for Asp. Lower doses of NT (0.05 microM) did not cause a significant change in ACh, GABA, or Asp output in the PFC. Higher concentrations of NT (2 microM) did not induce further increases in the level of neurotransmitters. A high-affinity selective neurotensin receptor (NTR1) antagonist SR 48692 (0.5 microM) perfused locally blocked neurotensin (1 microM)-evoked ACh, GABA, and Asp release. Local infusion of the sodium channel blocker tetrodotoxin (TTX) (1 microM) decreased the release of ACh, had no significant effect on GABA or Asp release, and prevented the 1 microM neurotensin-induced increase in ACh, GABA, and Asp output. Removal of calcium from the Ringers solution prevented the peptide from having any effects on the neurotransmitters. Thus, in vivo NT plays a modulatory role in the PFC by interacting with cortical neurons releasing GABA and Asp and with ACh-containing neurons projecting to the PFC. The NT effects are of neural origin, as they are TTX-sensitive, and mediated by the NTR1 receptor, as they are antagonized by SR 48692.

Collaboration


Dive into the Laura Della Corte's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Roberta J. Ward

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Frédéric Lallemand

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Philippe De Witte

Université catholique de Louvain

View shared research outputs
Top Co-Authors

Avatar

Wolfhardt Freinbichler

Vienna University of Technology

View shared research outputs
Researchain Logo
Decentralizing Knowledge